Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Udenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 19/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 0.64 |
| ▸ | PDE9A | O76083 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | PDE6C | P51160 | 1/20 | 0.64 |
| ▸ | PDE1A | P54750 | 1/20 | 0.64 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Udenafil SCHEMBL30452348 | 1.00 | PDE5A (1.00) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8054822 | 0.97 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055636 | 0.97 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055433 | 0.97 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055565 | 0.95 | PDE5A (0.91) | PDE5APDE2APDE9APDE4APDE6C | |
| SCHEMBL16850578 | 0.95 | PDE5A (0.91) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055012 | 0.94 | PDE5A (0.89) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055765 | 0.94 | PDE5A (0.89) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8066232 | 0.94 | PDE5A (0.89) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055102 | 0.94 | PDE5A (0.89) | PDE5APDE2APDE9APDE4APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 920 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| EP-2825208-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | Levicept Ltd. (GB) | 2015-01-21 | — | — | EP | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| WO-2013136078-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2013-09-19 | — | — | WO | claimed |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER INC. | 2009-04-30 | — | — | US | claimed |
| WO-2007072169-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF LUTS COMPRISING A PDE5 INHIBITOR AND A MUSCARINIC ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | claimed |
| JP-2006528229-A | — | — | 2006-12-14 | — | — | JP | claimed |
| WO-2006092691-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | claimed |
| US-20060148693-A1 | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | claimed |
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | NYCOMED GMBH (DE) | 2006-05-04 | — | — | US | claimed |
| EP-1638567-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA Pharma AG (DE) | 2006-03-29 | — | — | EP | claimed |
| EP-1628682-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA Pharma AG (DE) | 2006-03-01 | — | — | EP | claimed |
| WO-2004110450-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA PHARMA AG (DE) | 2004-12-23 | — | — | WO | claimed |
| WO-2004103407-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-12-02 | — | — | WO | claimed |
| US-20040132731-A1 | Novel combination | PFIZER, INC. | 2004-07-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | PDE5A 545/4885PDE2A 540/4885PDE9A 2785/4885 |
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | PDE5A, PDE12, PDE4A | PDE5A 1/4885PDE2A 8/4885PDE9A 10/4885 |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PDE7A, PDE7B, PDE3A | PDE5A 5/4885PDE2A 6/4885PDE9A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.